A primer on HIV type 1-specific immune function and REMUNE.

Moss, R B; Giermakowska, W K; Savary, J R; Theofan, G; Daigle, A E; Richieri, S P; Jensen, F C; Carlo, D J

Moss, R B; Giermakowska, W K; Savary, J R; Theofan, G; Daigle, A E; Richieri, S P; Jensen, F C; Carlo, D J.

Affiliation

Moss RB; The Immune Response Corporation, Carlsbad, California 92008, USA.

AIDS Res Hum Retroviruses ; 14 Suppl 2: S167-75, 1998 Jun.

Article in En | MEDLINE | ID: mdl-9672235

Subject(s)

AIDS Vaccines/therapeutic use; HIV Infections/immunology; HIV Infections/therapy; HIV-1/immunology; AIDS Vaccines/immunology; Adjuvants, Immunologic; Clinical Trials, Phase II as Topic; Double-Blind Method; HIV Infections/drug therapy; Humans; Immunotherapy

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / HIV-1 / AIDS Vaccines Type of study: Clinical_trials Limits: Humans Language: En Journal: AIDS Res Hum Retroviruses Journal subject: SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS) Year: 1998 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links